Effect of airflow limitation on acute exacerbations in patients with destroyed lungs by tuberculosis

Journal of Korean Medical Science

Volumn 30, Issue 6, 2015, Pages 737-742

  Kim, Soo Jung ^a   Lee, Jinwoo ^a   Park, Young Sik ^a   Lee, Chang Hoon ^a   Lee, Sang Min ^a   Yim, Jae Joon ^a   Kim, Young Whan ^a   Han, Sung Koo ^a   Yoo, Chul Gyu ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Acute exacerbation; Airflow limitation; Pulmonary function; Tuberculosis

Indexed keywords

COMORBIDITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DISEASES, OBSTRUCTIVE; LUNG FUNCTION TEST; MALE; MIDDLE AGED; PREVALENCE; RISK FACTOR; SOUTH KOREA; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS, PULMONARY;

COMORBIDITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; PREVALENCE; REPUBLIC OF KOREA; RESPIRATORY FUNCTION TESTS; RISK FACTORS; TUBERCULOSIS, PULMONARY;

EID: 84952642014     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2015.30.6.737     Document Type: Article

References (28)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-21.
2. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis. Chest 2007; 131: 1817-24.
3. Plit ML, Anderson R, Van Rensburg CE, Page-Shipp L, Blott JA, Fresen JL, Feldman C. Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J 1998; 12: 351-6.
4. Chae JN, Jung CY, Shim SW, Rho BH, Jeon YJ. CT Radiologic findings in patients with tuberculous destroyed lung and correlation with lung function. Tuberc Respir Dis 2011; 71: 202-9.
5. Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax 2000; 55: 32-8.
6. Lee SW, Kim YS, Kim DS, Oh YM, Lee SD. The risk of obstructive lung disease by previous pulmonary tuberculosis in a country with intermediate burden of tuberculosis. J Korean Med Sci 2011; 26: 268-73.
7. Chakrabarti B, Calverley PM, Davies PD. Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2007; 2: 263-72.
8. Jordan TS, Spencer EM, Davies P. Tuberculosis, bronchiectasis and chronic airflow obstruction. Respirology 2010; 15: 623-8.
9. Lee JH, Chang JH. Lung function in patients with chronic airflow obstruction due to tuberculous destroyed lung. Respir Med 2003; 97: 1237-42.
10. Seo YK, Lee CH, Lee HK, Lee YM, Park HK, Choi SB, Kim HG, Jang HJ, Yum HK, Lee SH. Differences between patients with TB-destroyed lung and patients with COPD admitted to the ICU. Tuberc Respir Dis 2011; 70: 323-9.
11. Lam KB, Jiang CQ, Jordan RE, Miller MR, Zhang WS, Cheng KK, Lam TH, Adab P. Prior TB, smoking, and airflow obstruction: a cross-sectional analysis of the Guangzhou Biobank Cohort Study. Chest 2010; 137: 593-600.
12. Perez-Padilla R, Fernandez R, Lopez Varela MV, Montes de Oca M, Muiño A, Tálamo C, Brito Jardim JR, Valdivia G, Baptista Menezes AM. Airflow obstruction in never smokers in five Latin American cities: the PLATINO study. Arch Med Res 2012; 43: 159-65.
13. Caballero A, Torres-Duque CA, Jaramillo C, Bolivar F, Sanabria F, Osorio P, Orduz C, Guevara DP, Maldonado D. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest 2008; 133: 343-9.
14. Elkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006; 61: 259-66.
15. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-38.
16. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007; 131: 696-704.
17. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Al M, Mölken MR. Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis 2010; 5: 435-44.
18. Aso H, Kondoh Y, Taniguchi H, Kimura T, Nishiyama O, Kato K, Kataoka K, Hasegawa Y. Noninvasive ventilation in patients with acute exacerbation of pulmonary tuberculosis sequelae. Intern Med 2010; 49: 2077-83.
19. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-12.
20. Lainscak M, von Haehling S, Doehner W, Sarc I, Jeric T, Ziherl K, Kosnik M, Anker SD, Suskovic S. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J Cachexia Sarcopenia Muscle 2011; 2: 81-6.
21. Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis 2012; 7: 95-9.
22. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, et al.; ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184-92.
23. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J.; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-89.
24. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54.
25. Wedzicha JA, Decramer M, Seemungal TA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J 2012; 40: 1545-54.
26. Jochmann A, Scherr A, Jochmann DC, Miedinger D, Török SS, Chhajed PN, Tamm M, Leuppi JD. Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort. Swiss Med Wkly 2012; 142: w13567.
27. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-8.
28. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-8.